These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 18061455

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT, Robert NJ.
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [Abstract] [Full Text] [Related]

  • 3. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D, Williamson D.
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
    Dixon JM.
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):849-59. PubMed ID: 16761928
    [Abstract] [Full Text] [Related]

  • 11. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
    Dixon JM.
    Breast; 2008 Aug; 17(4):353-60. PubMed ID: 18490163
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [Abstract] [Full Text] [Related]

  • 15. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
    Toi M, Yamashiro H, Tsuji W.
    Breast Cancer; 2009 Jul; 16(3):207-18. PubMed ID: 19259765
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT.
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [Abstract] [Full Text] [Related]

  • 18. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT.
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [Abstract] [Full Text] [Related]

  • 19. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
    Mamounas EP.
    Ann Surg Oncol; 2008 Mar; 15(3):691-703. PubMed ID: 18196346
    [Abstract] [Full Text] [Related]

  • 20. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R, Paridaens R.
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.